Developing a new treatment for Mild Cognitive Impairment in Alzheimer's Disease
Preclinical and early clinical development of a GABA-A a5 PAM
This study is testing a new oral medication called BPN-27473 to see if it can help improve memory and thinking skills in people with Mild Cognitive Impairment due to Alzheimer's Disease, offering hope for those who currently have limited treatment options.
Quick facts
| Grant type | U01 cooperative agreement |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Agenebio, INC. NIH-funded |
| Lab location | 1 site (Baltimore, UNITED STATES) |
| Project ID | NIH-10914059 on NIH RePORTER |
What this research studies
This research focuses on the development of BPN-27473, a selective oral medication designed to enhance the function of GABA-A α5 receptors in the brain. It aims to address Mild Cognitive Impairment (MCI) due to Alzheimer's Disease, a condition that currently lacks effective treatments. By targeting excessive activity in the hippocampus, which is linked to memory issues, the research seeks to improve cognitive function in patients. The approach is based on promising preclinical findings and aims to provide a new therapeutic option for individuals at risk of progressing to dementia.
Who could benefit from this research
Good fit: Ideal candidates for this research are adults aged 21 and older who are experiencing Mild Cognitive Impairment due to Alzheimer's Disease.
Not a fit: Patients with advanced Alzheimer's Disease or those without cognitive impairment may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a new treatment that significantly improves cognitive function and slows the progression of Alzheimer's Disease.
How similar studies have performed: Previous studies using similar approaches have shown promising results in reducing hippocampal overactivity and improving memory performance in related conditions.
Where this research is happening
Baltimore, UNITED STATES
- Agenebio, INC. — Baltimore, United States (Active)
Researchers
- Principal investigator: Payie, Kenneth G — Agenebio, INC.
- Study coordinator: Payie, Kenneth G
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.